Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 15, 2025 17:42 ET | Source: Bragar Eagel & Squire

PRAXIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Praxis Precision Medicines, Inc. on Behalf of Praxis Stockholders and Encourages Investors to Contact the Firm

Praxis stock fell 5.6% after Q2 2025 results revealed high adverse events and trial dropouts for seizure drug vormatrigine.
September 04, 2025 07:54 ET | Source: Bragar Eagel & Squire

Bragar Eagel & Squire, P.C. Is Investigating Praxis, Align, Lantheus, and Spirit and Encourages Investors to Contact the Firm

NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Praxis Precision...
August 23, 2025 09:32 ET | Source: Bragar Eagel & Squire

PRAXIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Praxis Precision Medicines, Inc. on Behalf of Praxis Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Praxis (PRAX) To Contact Him Directly To Discuss Their Options If you purchased or...
August 03, 2022 09:00 ET | Source: Praxis Precision Medicines, Inc.

Praxis Precision Medicines to Present at 2022 Wedbush PacGrow Healthcare Conference

BOSTON, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
May 11, 2022 09:00 ET | Source: Praxis Precision Medicines, Inc.

Praxis Precision Medicines to Present at Upcoming Investor Conferences

BOSTON, May 11, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
May 09, 2022 16:01 ET | Source: Praxis Precision Medicines, Inc.

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2022 Financial Results

PRAX-944 demonstrated clinically meaningful functional improvement in essential tremor patients in Part B of Phase 2a study PRAX-114 Phase 2/3 monotherapy MDD Aria Study completed; topline results...
May 09, 2022 16:01 ET | Source: Praxis Precision Medicines, Inc.

Praxis Precision Medicines Reports Positive Topline Results from PRAX-944 Phase 2a Study in Essential Tremor Patients

PRAX-944 demonstrated clinically meaningful functional improvement in essential tremor patients in Part B of Phase 2a study Mean improvement at Day 42 was 42% as measured by Modified ADL, followed by...
April 13, 2022 08:00 ET | Source: Praxis Precision Medicines, Inc.

Praxis Precision Medicines to Host Epilepsy Day on April 27, 2022

BOSTON, April 13, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
February 22, 2022 09:00 ET | Source: Praxis Precision Medicines, Inc.

Praxis Precision Medicines to Provide Corporate Update and Report Fourth Quarter and Full Year 2021 Financial Results on Monday, February 28, 2022

BOSTON, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
December 02, 2021 07:00 ET | Source: Praxis Precision Medicines, Inc.

Praxis Precision Medicines Announces Management Team Appointments

BOSTON, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...